Arcturus Therapeutics
ARCT
139 hedge funds and large institutions have $736M invested in Arcturus Therapeutics in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 46 reducing their positions, and 34 closing their positions.
174% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $10.6M
3.29% more ownership
Funds ownership: 72.41% → 75.71% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 46
11% less funds holding
Funds holding: 156 → 139 (-17)
19% less capital invested
Capital invested by funds: $909M → $736M (-$173M)
44% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$26.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$23.9M |
| 3 |
Goldman Sachs
New York
|
+$5.39M |
| 4 |
JP Morgan Chase
New York
|
+$4.92M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$4.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$16.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.21M |
| 3 |
Millennium Management
New York
|
-$4.26M |
| 4 |
ACM
Altium Capital Management
New York
|
-$3.82M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.32M |
ARCT Hedge Fund Activity: Q4 2021 in Review
139 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2021, worth a combined $736M — down 19% from $909M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ARCT and 19 opened new positions — a net loss of 15 holders — while 46 trimmed existing stakes and 46 added.
The largest buyer was Federated Hermes, adding an estimated $26.5M. The largest seller was Bank Julius Baer & Co, cutting an estimated $16.9M.
- 139 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2021, down from 156 in Q3 2021.
- Funds reported $736M of Arcturus Therapeutics stock for Q4 2021, down 19% quarter-over-quarter.
- 19 funds opened new Arcturus Therapeutics positions in Q4 2021 and 34 closed out, a net change of -15 holders.
- The largest Arcturus Therapeutics buyer in Q4 2021 was Federated Hermes, an estimated $26.5M added.
- The largest Arcturus Therapeutics seller in Q4 2021 was Bank Julius Baer & Co, an estimated $16.9M sold.
Based on aggregated 13F filings for Q4 2021.